[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@yusufhameed Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::47121634.png) @yusufhameed Yusuf Hameed, MD

Yusuf Hameed, MD posts on X about $sgmo, $crsp, $edit, $beam the most. They currently have XXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::47121634/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47121634/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +140%

### Mentions: X [#](/creator/twitter::47121634/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47121634/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XXX -XX%
- X Months XXX -XX%
- X Year XXXXX +82%

### Followers: XXXXX [#](/creator/twitter::47121634/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47121634/c:line/m:followers.svg)

- X Week XXXXX +0.23%
- X Month XXXXX +1.90%
- X Months XXXXX +14%
- X Year XXXXX +13%

### CreatorRank: undefined [#](/creator/twitter::47121634/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::47121634/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::47121634/influence)
---

**Social category influence**
[cryptocurrencies](/list/cryptocurrencies)  XXX% [stocks](/list/stocks)  XXX% [technology brands](/list/technology-brands)  XXX% [finance](/list/finance)  XXX% [ncaa football](/list/ncaa-football)  XXX%

**Social topic influence**
[$sgmo](/topic/$sgmo) #10, [$crsp](/topic/$crsp) #15, [$edit](/topic/$edit) #5, [$beam](/topic/$beam) #48, [$ntla](/topic/$ntla) #16, [$qure](/topic/$qure) #21, [$lly](/topic/$lly) #108, [$rhhby](/topic/$rhhby) #10, [$vrtx](/topic/$vrtx) #10, [$pgen](/topic/$pgen) #2

**Top accounts mentioned or mentioned by**
[@sangamotx](/creator/undefined) [@jimcramer](/creator/undefined) [@seckennedy](/creator/undefined) [@potus](/creator/undefined) [@biotechanalysst](/creator/undefined) [@drmakaryfda](/creator/undefined) [@vprasadmdmph](/creator/undefined) [@cigna](/creator/undefined) [@cathiedwood](/creator/undefined) [@sandymacrae23](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@bpharmcatalyst](/creator/undefined) [@elonmusk](/creator/undefined) [@uhc](/creator/undefined) [@humana](/creator/undefined) [@anthembcbs](/creator/undefined) [@martymakary](/creator/undefined) [@darrenestes](/creator/undefined) [@wnba](/creator/undefined) [@gamalielbaer](/creator/undefined)

**Top assets mentioned**
[CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [BEAM (BEAM)](/topic/$beam) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [uniQure N.V. (QURE)](/topic/$qure) [Eli Lilly and Company (LLY)](/topic/$lly) [Vertex Protocol (VRTX)](/topic/$vrtx)
### Top Social Posts [#](/creator/twitter::47121634/posts)
---
Top posts by engagements in the last XX hours

"Job openings added to $SGMO over the last couple months. Not a sign of contracting. $CRSP $EDIT $BEAM $NTLA $QURE $PGEN $LLY $RHHBY $VRTX"  
[X Link](https://x.com/yusufhameed/status/1978190651863740540) [@yusufhameed](/creator/x/yusufhameed) 2025-10-14T20:06Z 1714 followers, 1487 engagements


"Gene therapy companies need a rethink $SGMO $CRSP $EDIT $BEAM $NTLA $PGEN $QURE $LLY $RHHBY $VRTX $TAK"  
[X Link](https://x.com/yusufhameed/status/1978933086478913845) [@yusufhameed](/creator/x/yusufhameed) 2025-10-16T21:16Z 1714 followers, 1204 engagements


"$SGMO $CRSP $EDIT $BEAM $NTLA $QURE $LLY $RHHBY $VRTX If and WHEN @SangamoTx secures a Fabry partnership deal find a suitable AI partner like @IsomorphicLabs @insitro. Biotech specialists like Isomorphic Labs or Insitro could edge out @OpenAI with deeper gene therapy expertise but OpenAI's scale shines for custom models. Weigh IP costs & pilots #BiotechAI #GeneTherapy"  
[X Link](https://x.com/yusufhameed/status/1978109751213887670) [@yusufhameed](/creator/x/yusufhameed) 2025-10-14T14:44Z 1715 followers, 2101 engagements


"@AOC says it so it must be true @DeloitteUS pivots to manufacturing and poisons our waterways Interesting"  
[X Link](https://x.com/yusufhameed/status/1978962364234899578) [@yusufhameed](/creator/x/yusufhameed) 2025-10-16T23:12Z 1714 followers, XX engagements


"Why is $EDIT up I remember the low being $XXXX $SGMO missing out on the biotech momentum trade. $CRSP $EDIT $BEAM $NTLA $PGEN $QURE"  
[X Link](https://x.com/yusufhameed/status/1978469128387056035) [@yusufhameed](/creator/x/yusufhameed) 2025-10-15T14:32Z 1715 followers, XXX engagements


"Imagine waking up to this $SGMO shareholders wondering what you did wrong. $SPRB shorts so screwed. Enzyme replacement therapy is not the answer long term but what a ride @wallstreetbets @jimcramer @JoeSquawk $150M market cap today. $5M yesterday"  
[X Link](https://x.com/yusufhameed/status/1975488108583133432) [@yusufhameed](/creator/x/yusufhameed) 2025-10-07T09:07Z 1714 followers, 3534 engagements


"$SGMO $CRSP $EDIT $BEAM $NTLA Crispr dominating conversation with @CathieDWood. @adamfeuerstein hates @SangamoTx. Why"  
[X Link](https://x.com/yusufhameed/status/1976224525944750547) [@yusufhameed](/creator/x/yusufhameed) 2025-10-09T09:53Z 1715 followers, XXX engagements


"$SGMO doing all the right things except announcing Fabry partnership. Pain studies could be a game changer. I would love to give an intrathecal injection for chronic pain patients that really works. $CRSP $EDIT $BEAM $NTLA $QURE $LLY $RHHBY $VRTX"  
[X Link](https://x.com/yusufhameed/status/1978178003134787801) [@yusufhameed](/creator/x/yusufhameed) 2025-10-14T19:16Z 1715 followers, 1840 engagements


"@USC Foreign grad student raping women for years by drugging them finally caught"  
[X Link](https://x.com/yusufhameed/status/1979094721910780240) [@yusufhameed](/creator/x/yusufhameed) 2025-10-17T07:58Z 1715 followers, X engagements


"Sangamo's focus on hemophilia A complements the hemophilia B dominance of etranacogene dezaparvovec (Hemgenix uniQure/CSL) and fidanacogene elaparvovec (Beqvez Pfizer). It addresses a larger patient population (80% of hemophilia cases are type A) but faces challenges like FVIII expression durability (similar to Roctavian's decline over time) and AAV immunity exclusion (40% of patients). If partnered successfully giroctocogene could challenge Roctavian's market share with potentially more stable expression"  
[X Link](https://x.com/yusufhameed/status/1979097075275981068) [@yusufhameed](/creator/x/yusufhameed) 2025-10-17T08:08Z 1713 followers, XXX engagements